Female Sexual Dysfunction Drug Addyi Faces Yet Another Setback The FDA is considering possible regulatory action, due to a spike in reported adverse events associated with the drug Addyi (flibanserin), which is indicated for hypoactive sexual desire disorder. This isn’t the first setback in Addyi’s six year history.